Curated News
By: NewsRamp Editorial Staff
September 03, 2024
Clene (NASDAQ: CLNN) Leads the Charge in Treating Neurodegenerative Diseases
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Clene Inc. is at the forefront of transforming the treatment of neurodegenerative disorders, potentially altering the course of these debilitating conditions.
- CNM-Au8 targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function by improving cellular energy production and utilization.
- Clene's innovative approach aims to provide neuroprotection and promote remyelination, potentially making tomorrow better for those suffering from neurodegenerative diseases.
- CNM-Au8 works by improving cellular energy production and utilization, essential for maintaining neurological health, potentially altering the course of neurodegenerative diseases.
Impact - Why it Matters
This news matters because Clene's innovative approach with CNM-Au8 has the potential to alter the course of debilitating conditions like ALS and MS. With extensive clinical trials and a strong safety profile, the company is positioned as a leader in addressing neurodegenerative diseases, offering hope to patients and investors alike.
Summary
Clene (NASDAQ: CLNN), a biopharmaceutical company, is advancing treatment for neurodegenerative disorders like ALS and MS with its lead agent, CNM-Au8, targeting the NAD+ pathway to improve cellular energy production and utilization. Extensive clinical trials have shown CNM-Au8's strong safety profile, positioning Clene as a leader in addressing neurodegenerative diseases. The company is gearing up for phase three programs for both ALS and MS, backed by strong intellectual property and over 150 patients worldwide.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) Leads the Charge in Treating Neurodegenerative Diseases
